History｜Sawai Group Holdings
Sawai’s Pitavastatin tablets approved by the U.S. Food and Drug Administration (FDA). This made Sawai the first Japanese generic drug maker whose Paragraph IV Abbreviated New Drug Application (ANDA) was approved by the FDA.
Investor Relations｜Sawai Group Holdings
Message on Management Policies from Mitsuo Sawai, Chairman and Group CEO Medium-Term Business Plan Our latest long-term vision for 2030 and medium-term business plan
Sawai Group Holdings
Sawai Receives Approvals for Six Generic Drugs with 11 Strengths Opens in a new window.
Sawai Pharmacy, the forerunner of Sawai Pharmaceutical Co., Ltd. was established as a drugstore in 1929. Subsequently, in the years before and after the Second World War when pharmaceutical products were in short supply, Sawai transformed itself into a manufacturer of over-the-counter pharmaceutical products in order to meet society’s needs.
About Us｜Sawai Group Holdings
Outline of the business and structure of Sawai Group. Group Companies. Introduction of Group companies. Long-Term Vision and Mid-Term Business Plan. Our latest long-term vision for 2030 and medium-term business plan. Global Policies. Global policies set by the Sawai Group. Sawai Group Holdings. News. Press release. About Us.
Group Companies｜Sawai Group Holdings
Sawai Pharmaceutical Co., Ltd. Main Business: Manufacturing and sales of ethical pharmaceuticals, centering on generic drugs, in Japan. Founded: July 1, 1948. Headquarters: 5-2-30, Miyahara, Yodogawa-ku, Osaka, Japan. President: Motohiko Kimura. Shareholding Ratio: 100%. URL：https://global.sawai.co.jp/
Japanese generics business | Sawai Group Holdings Integrated …
Because both projects progressed as planned, we increased our production capacity by 5.0 billion tablets. However, as of May 13, 2024, there continued to be limited shipments of 249 items, and thus we still have a responsibility to meet the expectations placed on Sawai Pharmaceutical to dramatically improve the situation and provide a stable ...
Sawai Group Holdings and ORIX Agree on Conclusion of Transfer …
Dec 3, 2021 · Sawai Group’s in-house production capacity is being reinforced in stages by the construction of the new solid dosage form facility at the Daini Kyushu Factory announced in October 2021, the opening of the Daini East Japan Distribution Center in November 2021, and this Transfer Agreement.
Business and Structure of Sawai Group｜Sawai Group Holdings
Sawai Pharmaceutical has established the position as one of the leading companies in the generics market in Japan by contributing to reducing the medical expense burden on patients and medical costs. Overview Diagram
Sawai Group Holdings Integrated Report 2024
Representative Director, Chairman, and President Mitsuo Sawai explains recurrence prevention measures in response to inappropriate testing at Sawai Pharmaceutical as well as future growth initiatives.